Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons

Elizabeth J. Carey, Keith Lindor

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Animal and human data suggest a relationship between bile acids, especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal and . in vitro studies to reduce the risk of colonic dysplasia and cancer development. Human trials have focused on patients with history of adenoma, inflammatory bowel disease, primary sclerosing cholangitis, and primary biliary cirrhosis. Some studies suggest that ursodeoxycholic may reduce the colorectal cancer risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for colorectal cancer chemoprophylaxis.

Original languageEnglish (US)
JournalClinics and Research in Hepatology and Gastroenterology
Volume36
Issue numberSUPPL.1
DOIs
StatePublished - Sep 2012

Fingerprint

Ursodeoxycholic Acid
Chemoprevention
Bile Acids and Salts
Colorectal Neoplasms
Sclerosing Cholangitis
Biliary Liver Cirrhosis
Inflammatory Bowel Diseases
Adenoma
Colonic Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Chemoprevention of colorectal cancer with ursodeoxycholic acid : Cons. / Carey, Elizabeth J.; Lindor, Keith.

In: Clinics and Research in Hepatology and Gastroenterology, Vol. 36, No. SUPPL.1, 09.2012.

Research output: Contribution to journalArticle

@article{813ce30aa6a145ca8366d1ed9ba30fd5,
title = "Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons",
abstract = "Animal and human data suggest a relationship between bile acids, especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal and . in vitro studies to reduce the risk of colonic dysplasia and cancer development. Human trials have focused on patients with history of adenoma, inflammatory bowel disease, primary sclerosing cholangitis, and primary biliary cirrhosis. Some studies suggest that ursodeoxycholic may reduce the colorectal cancer risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for colorectal cancer chemoprophylaxis.",
author = "Carey, {Elizabeth J.} and Keith Lindor",
year = "2012",
month = "9",
doi = "10.1016/S2210-7401(12)70023-2",
language = "English (US)",
volume = "36",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",
number = "SUPPL.1",

}

TY - JOUR

T1 - Chemoprevention of colorectal cancer with ursodeoxycholic acid

T2 - Cons

AU - Carey, Elizabeth J.

AU - Lindor, Keith

PY - 2012/9

Y1 - 2012/9

N2 - Animal and human data suggest a relationship between bile acids, especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal and . in vitro studies to reduce the risk of colonic dysplasia and cancer development. Human trials have focused on patients with history of adenoma, inflammatory bowel disease, primary sclerosing cholangitis, and primary biliary cirrhosis. Some studies suggest that ursodeoxycholic may reduce the colorectal cancer risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for colorectal cancer chemoprophylaxis.

AB - Animal and human data suggest a relationship between bile acids, especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal and . in vitro studies to reduce the risk of colonic dysplasia and cancer development. Human trials have focused on patients with history of adenoma, inflammatory bowel disease, primary sclerosing cholangitis, and primary biliary cirrhosis. Some studies suggest that ursodeoxycholic may reduce the colorectal cancer risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for colorectal cancer chemoprophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=84868712865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868712865&partnerID=8YFLogxK

U2 - 10.1016/S2210-7401(12)70023-2

DO - 10.1016/S2210-7401(12)70023-2

M3 - Article

C2 - 23141896

AN - SCOPUS:84868712865

VL - 36

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

IS - SUPPL.1

ER -